Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 819, pseudogene (RNU6-819P) is a **pseudogene** derived from the U6 small nuclear RNA (snRNA) family[1][5]. U6 snRNA itself is a critical non-coding RNA involved in splicing of pre-messenger RNA as part of the spliceosomal complex, but pseudogenes like RNU6-819P are typically nonfunctional copies generated by retrotransposition events[1][5]. These pseudogenes generally do not encode active products and do not participate in canonical molecular or therapeutic target roles. Some pseudogenes may be transcribed and act as regulatory non-coding RNAs in certain contexts, but there is no current evidence implicating RNU6-819P in specific molecular functions or diseases[1][2][4][5]. Pseudogenes of U6 snRNA are mainly markers of retrotransposon activity and genome evolution, not therapeutic or druggable targets[5]. **Essential context:** - This entry is not a conventional molecular target (like a receptor, enzyme, or transporter)[1][3][5]. - It is a **pseudogene**, which means it is a defunct copy of a functional gene; such loci usually do not have protein-coding or therapeutic relevance. - U6 snRNA pseudogenes (including RNU6-819P) can occasionally be transcribed or participate in regulatory networks as non-coding RNAs in rare cases, but these properties are not general or established for this specific pseudogene[2][4]. - There are **no drugs, biomarkers, mechanisms of action**, or direct disease roles associated with RNU6-819P. **Note:** There is nothing inherently "incorrect" about the spelling or locus name, but this is not a valid pharmacological or therapeutic target, hence is_incorrect is set to true for practical indexing as a drug or biological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 819, pseudogene (RNU6-819P).